NMBP-13-2017: Cross-cutting KETs for diagnostics at the point-of-care

co-funded by LEIT-NMBP (DG RTD) and LEIT-ICT (DG CONNECT)

Opening 20 Sep 2016
***Closing* 19 Jan 2017**
Single stage submission

Andreas.Iymberis@ec.europa.eu
Heico.frima@ec.europa.eu

15 M€ - 100% funding

Research & Innovation Actions (RIA) 3 - 5 M€ per proposal

Cross-cutting KETs



EU Funding for Medtech and nanomedicine

FP7 (2007 – 2014)

Total ~ € 730 million funding to 155 projects

- NMP - 85 Projects, ~ 430 mio € funding

Diagnostics & imaging, (targeted) nanopharmaceutics, biomaterials for implants and regenerative medicine, neuro-nano / smart implants

- ICT MNBS - 39 projects, ~ 145 mio €

- HEALTH - 31 Projects ~ 150 mio €

Excluding: European Research Council, Marie-Curie

HORIZON 2020 – Workprogramme 2014

Total ~ 530 million € EU funding to 280 projects

Programmes:

LEIT: NMBP + ICT (NMBS) + SME Instrument

Societal Challenge 1 (HEALTH) + SME Instrument

INFRASTRUCTURE

European Research Council

Marie-Skledowska-Curie Training Networks and Bursaries

NMBP-13 – Objective & Requirements

Objective: *further development into a clinical setting of novel MNBS platforms, techniques and systems that have already been proven in a laboratory setting (laboratory Proof-of-Concept)*

Focus applications:

- ✓ *In vitro/in vivo diagnostics that are deployed at the point of care;*
- ✓ *Therapy monitoring at the point of care.*

The work includes:

Translation from the pre-clinical phase to early clinical testing, including design and pilot manufacturing in appropriate volume for clinical testing (small series), pre-clinical and early clinical testing.

include a business case and exploitation strategy

Facilitate clinical data harvesting

Demonstrate clear compliance with applicable Good Laboratory /Clinical / Manufacturing Practices

Attention to the requirements for Health Technology Assessment (HTA); Standardisation issues; Gender specific issues

MNBP-13 – RIA Scope

RIA - Research & Innovation Actions

Novel MNBS Platforms / Techniques / Systems

Validation in pre-clinical & clinical test settings:

- *prototyping,*
- *design and pilot manufacturing*
- *small series manufacturing,*
- *pre-clinical and clinical testing,*
- *clinical data harvesting*

Validated in clinical setting, addressing real needs in applications of:

- *In vitro/in vivo diagnostics that are deployed at the point of care;*
- *Therapy monitoring at the point of care.*

- **TRLs 3-4 to 5-6**
- **Activities of direct clinical & industrial relevance**
- **Medium time to market**

NMBP-13 – RIA - Expected Impact

Research & Innovation Actions



- *Progress the development of advanced integrated MNBS based diagnostic health platforms, techniques or systems from the laboratory Proof-of-Concept to the clinical setting;*

- *Establish a world-class European competitive industrial R&D and manufacturing competence in Micro-Nano-Bio Systems integration for healthcare diagnostics applications;*
- *Strengthening the industrial value chain and progress to marketisation;*
- *Provide affordable systems with unique features that address specific well identified requirements in healthcare;*

- *Address priority needs in healthcare diagnostics and / or therapy monitoring, for the benefit of patients;*
- *Early involvement of regulatory bodies and patients in the new developments*

Thank you for your attention

Information and Consultation Day on x-KETs for Health: Brussels, 13 September 2016

Research in Key Enabling Technologies:
http://ec.europa.eu/research/industrial_technologies/

Digital Agenda for Europe – Components and Systems:
https://ec.europa.eu/digital-agenda/en/science-and-technology/components-systems

Horizon 2020 on the web: http://ec.europa.eu/research/horizon2020/index_en.cfm